725 related articles for article (PubMed ID: 25938284)
1. The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease.
O'Brien ME; Pennycooke K; Carroll TP; Shum J; Fee LT; O'Connor C; Logan PM; Reeves EP; McElvaney NG
COPD; 2015 May; 12 Suppl 1():2-9. PubMed ID: 25938284
[TBL] [Abstract][Full Text] [Related]
2. The national alpha-1 antitrypsin deficiency registry in Poland.
Chorostowska-Wynimko J; Struniawski R; Sliwinski P; Wajda B; Czajkowska-Malinowska M
COPD; 2015 May; 12 Suppl 1():22-6. PubMed ID: 25938287
[TBL] [Abstract][Full Text] [Related]
3. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD.
Green CE; Vayalapra S; Hampson JA; Mukherjee D; Stockley RA; Turner AM
Thorax; 2015 Oct; 70(10):939-45. PubMed ID: 26141072
[TBL] [Abstract][Full Text] [Related]
4. Spanish Registry of Patients With Alpha-1 Antitrypsin Deficiency; Comparison of the Characteristics of PISZ and PIZZ Individuals.
Lara B; Miravitlles M
COPD; 2015 May; 12 Suppl 1():27-31. PubMed ID: 25938288
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in alpha-1-antitrypsin deficiency lung disease-analysis from the German registry.
Fähndrich S; Herr C; Greulich T; Seibert M; Lepper PM; Bernhard N; Lützow C; Vogelmeier C; Bals R
COPD; 2015 May; 12 Suppl 1():58-62. PubMed ID: 25938294
[TBL] [Abstract][Full Text] [Related]
6. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
7. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT).
Esquinas C; Serreri S; Barrecheguren M; Rodriguez E; Nuñez A; Casas-Maldonado F; Blanco I; Pirina P; Lara B; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2018; 13():1001-1007. PubMed ID: 29615836
[TBL] [Abstract][Full Text] [Related]
8. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Int J Chron Obstruct Pulmon Dis; 2017; 12():1427-1437. PubMed ID: 28553095
[TBL] [Abstract][Full Text] [Related]
9. The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency.
Piitulainen E; Tanash HA
COPD; 2015 May; 12 Suppl 1():36-41. PubMed ID: 25938290
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Alpha-1 Antitrypsin Deficiency.
Strange C; Beiko T
Semin Respir Crit Care Med; 2015 Aug; 36(4):470-7. PubMed ID: 26238635
[TBL] [Abstract][Full Text] [Related]
11. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
Stockley RA; Edgar RG; Pillai A; Turner AM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1745-56. PubMed ID: 27536086
[TBL] [Abstract][Full Text] [Related]
12. Unique and shared systemic biomarkers for emphysema in Alpha-1 Antitrypsin deficiency and chronic obstructive pulmonary disease.
Serban KA; Pratte KA; Strange C; Sandhaus RA; Turner AM; Beiko T; Spittle DA; Maier L; Hamzeh N; Silverman EK; Hobbs BD; Hersh CP; DeMeo DL; Cho MH; Bowler RP
EBioMedicine; 2022 Oct; 84():104262. PubMed ID: 36155958
[TBL] [Abstract][Full Text] [Related]
13. Bacterial load and inflammatory response in sputum of alpha-1 antitrypsin deficiency patients with COPD.
Balbi B; Sangiorgi C; Gnemmi I; Ferrarotti I; Vallese D; Paracchini E; Delle Donne L; Corda L; Baderna P; Corsico A; Carone M; Brun P; Cappello F; Ricciardolo FL; Ruggeri P; Mumby S; Adcock IM; Caramori G; Di Stefano A
Int J Chron Obstruct Pulmon Dis; 2019; 14():1879-1893. PubMed ID: 31686800
[TBL] [Abstract][Full Text] [Related]
14. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
15. The United States Alpha-1 Foundation Research Registry: Genesis, Impact and Future.
Strange C; Monk R; Schwarz L; Walker D; Kumbhare S; Bieko T
COPD; 2015 May; 12 Suppl 1():42-5. PubMed ID: 25938291
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in patients with alpha-1 antitrypsin deficiency: the French experience.
Gauvain C; Mornex JF; Pison C; Cuvelier A; Balduyck M; Pujazon MC; Fournier M; AitIlalne B; Thabut G
COPD; 2015 May; 12 Suppl 1():46-51. PubMed ID: 25938292
[TBL] [Abstract][Full Text] [Related]
17. Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency.
Franciosi AN; Hobbs BD; McElvaney OJ; Molloy K; Hersh C; Clarke L; Gunaratnam C; Silverman EK; Carroll TP; McElvaney NG
Am J Respir Crit Care Med; 2020 Jul; 202(1):73-82. PubMed ID: 32197047
[No Abstract] [Full Text] [Related]
18. Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol.
Strange C; Senior RM; Sciurba F; O'Neal S; Morris A; Wisniewski SR; Bowler R; Hochheiser HS; Becich MJ; Zhang Y; Leader JK; Methé BA; Kaminski N; Sandhaus RA;
Ann Am Thorac Soc; 2015 Oct; 12(10):1551-60. PubMed ID: 26153726
[TBL] [Abstract][Full Text] [Related]
19. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal decline of diffusing capacity of the lung for carbon monoxide in community subjects with the PiMZ alpha1-antitrypsin phenotype.
Silva GE; Guerra S; Keim S; Barbee RA; Sherrill DL
Chest; 2008 May; 133(5):1095-100. PubMed ID: 18263681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
